

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
11 December 2003 (11.12.2003)

PCT

(10) International Publication Number  
WO 2003/102012 A3

(51) International Patent Classification<sup>7</sup>: C07J 1/00,  
A61K 31/565, A61P 5/34, 15/16, 15/18

(21) International Application Number:  
PCT/EP2003/050187

(22) International Filing Date: 22 May 2003 (22.05.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
02077119.2 30 May 2002 (30.05.2002) EP

(71) Applicant (for all designated States except US): AKZO  
NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Am-  
hem (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): DE NIJS, Henrik  
[NL/NL]; N.V. Organon, P.O. Box 20, NL-5340 BH Oss

(NL). VAN DER VOORT, Hendrikus Adrianus Anto-  
nius [NL/NL]; N.V. Organon, P.O. Box 20, NL-5340 BH  
Oss (NL). LEYSEN, Dirk [BE/NL]; N.V. Organon, P.O.  
Box 20, NL-5340 BH Oss (NL). GROOTENHUIS, Arij  
Jan [NL/NL]; N.V. Organon, P.O. Box 20, NL-5340 BH  
Oss (NL).

(74) Agent: VAN DEN BROEK, Ludovicus A.G.M.; P.O.  
Box 20, NL-5340 BH Oss (NL).


(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,  
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),

[Continued on next page]

(54) Title: NEW ETONOGESTREL ESTERS

(57) Abstract: The subject invention provides new progestogen esters and  
uses thereof.





Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

**(88) Date of publication of the international search report:**

22 April 2004

**(15) Information about Correction:**

**Previous Correction:**

see PCT Gazette No. 12/2004 of 18 March 2004, Section II

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Patent Application No.**

PCT/EP 03/50187

**A. CLASSIFICATION OF SUBJECT MATTER**

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07J1/00 A61K31/565 A61P5/34 A61P15/16 A61P15/18

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07J A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

### C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 737 477 A (AKZO NOBEL NV) 16 October 1996 (1996-10-16) the whole document ----	1-10,16
Y	DE 196 13 698 A (SCHERING AG) 23 January 1997 (1997-01-23) the whole document ----	1-10,16
A	EP 0 129 947 A (WORLD HEALTH ORG) 2 January 1985 (1985-01-02) the whole document ----- -/--	1,3



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

<sup>o</sup> Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

**"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone**

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

6 November 2003

Date of mailing of the International search report

17/11/2003

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer \_\_\_\_\_

de Nooy, A

## INTERNATIONAL SEARCH REPORT

1st Application No

PCT/EP 03/50187

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>GUERIN J F ET AL: "INHIBITION OF SPERMATOGENESIS IN MEN USING VARIOUS COMBINATIONS OF ORAL PROGESTAGENS AND PERCUTANEOUS OR ORAL ANDROGENS" INTERNATIONAL JOURNAL OF ANDROLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 11, no. 3, 1988, pages 187-199, XP000917371 ISSN: 0105-6263 cited in the application the whole document</p> <p>-----</p>	3

# INTERNATIONAL SEARCH REPORT

Application No  
PCT/EP 03/50187

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0737477	A	16-10-1996	AU 692504 B2	11-06-1998
			AU 1281895 A	17-07-1995
			BR 9408457 A	05-08-1997
			EP 0737477 A1	16-10-1996
			FI 962618 A	25-06-1996
			NO 962694 A	26-06-1996
			NZ 277552 A	26-01-1998
			CA 2176824 A1	06-07-1995
			CN 1135716 A	13-11-1996
			CZ 9601877 A3	15-01-1997
			HU 75159 A2	28-04-1997
			WO 9517896 A1	06-07-1995
			ZA 9410333 A	04-12-1995
DE 19613698	A	23-01-1997	DE 19613698 A1	23-01-1997
			AU 6614096 A	18-02-1997
			WO 9703709 A1	06-02-1997
			EP 0848620 A1	24-06-1998
			JP 11509222 T	17-08-1999
			ZA 9606083 A	19-06-1998
EP 0129947	A	02-01-1985	AT 37185 T	15-09-1988
			DE 3474024 D1	20-10-1988
			EP 0129947 A2	02-01-1985

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
11 December 2003 (11.12.2003)

PCT

(10) International Publication Number  
**WO 2003/102012 A3**

(51) International Patent Classification<sup>7</sup>:  
A61K 31/565, A61P 5/34, 15/16, 15/18

C07J 1/00,

(72) Inventors; and

(21) International Application Number:

PCT/EP2003/050187

(22) International Filing Date: 22 May 2003 (22.05.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

02077119.2

30 May 2002 (30.05.2002) EP

(74) Agent: VAN DEN BROEK, Ludovicus A.G.M.; P.O. Box 20, NL-5340 BH Oss (NL).


(71) Applicant (for all designated States except US): AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,

[Continued on next page]

(54) Title: NEW ETONOGESTREL ESTERS

(57) Abstract: The subject invention provides new progestogen esters and uses thereof.





MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

**(84) Designated States (regional):** ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

**(88) Date of publication of the international search report:**  
22 April 2004

**(48) Date of publication of this corrected version:**  
13 January 2005

**(15) Information about Corrections:**  
see PCT Gazette No. 02/2005 of 13 January 2005, Section II  
**Previous Correction:**  
see PCT Gazette No. 12/2004 of 18 March 2004, Section II

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## NEW ETONOGESTREL ESTERS

### FIELD OF THE INVENTION

5

The subject invention concerns the field of (female and male) contraception, (female and male) hormone replacement therapy (HRT) and treatment/prevention of gynaecological disorders.

10 

### BACKGROUND

Contraceptive methods for men and women are important for worldwide reproductive health.

15 

However, no effective and efficient methods of male contraception are as of yet available.

Male contraception seeks to suppress spermatogenesis through the suppression of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

20 

This results in a depletion of intratesticular testosterone and cessation of spermatogenesis.

25 

Administration of progestagen results in a dose dependent suppression of pituitary gonadotrophins and consequently, a decrease in testosterone levels and a reversible inhibition of spermatogenesis. An exogenous androgen is required to compensate for the reduced testosterone levels. In the same way, male HRT can be accomplished, resulting in replacement of testosterone by an exogenous androgen which is safer on the prostate than endogenous testosterone.

30 

The use of progestogens together with androgens for use as male contraceptives is known (Guerin and Rollet (1988), *International Journal of Andrology* 11, 187-199).

However, the use of specific esters of etonogestrel for male contraception and male HRT has not been suggested.



In addition, the use of progestogens together with estrogens for use in female contraception is known (M. Tausk, J.H.H. Thijssen, Tj.B. van Wimersma Greidanus, "Pharmakologie der Hormone", Georg Thieme Verlag, Stuttgart, 1986).

5

Progestagens are widely used for female contraception and in female HRT. In contraception, the combination progestagen-estrogen oral contraceptives are the most widely used. Administration of such a combination results in a number of effects: it blocks ovulation, it interferes with phasic development of the endometrium which decreases the chance for successful implantation, and it causes the cervical mucus to become so viscous that it hinders sperm penetration. Most progestagen-only-pills (POP's) aim at the last mentioned effect only.

Female HRT is aimed at suppletion of endogenous estrogen for the treatment of peri- and postmenopausal complaints (hot flushes, vaginal dryness), and for prevention of symptoms of long-term estrogen deficiency. The latter include osteoporosis, coronary artery disease, urogenital incontinence, and possibly also Alzheimer's disease and colorectal cancer. A drawback of long-term unopposed estrogen administration is the associated increase in endometrium proliferation, which in turn may increase the risk of endometrial cancer. For that reason, progestagens are co-administered in long-term regimes, because of their ability to reduce the proliferative activity of endometrial epithelium and to induce secretory conversion.

However, the use of specific esters of etonogestrel for female contraception, female HRT and treatment/prevention of gynaecological disorders has not been suggested.

The subject invention describes new esters of etonogestrel, i.e. etonogestrel dodecanoate, etonogestrel undecanoate, and etonogestrel dodecanoate which have surprisingly been found to have a better pharmacokinetic profile than other etonogestrel esters. These esters enable a single-dose administration of a progestogen with a long duration of action.

## SUMMARY OF THE INVENTION

The subject invention provides new progestogen esters, i.e. etonogestrel decanoate, etonogestrel undecanoate, and etonogestrel dodecanoate and uses thereof for both male and female contraception and male and female HRT.

In addition, the use of these esters for treatment and prevention of female gynaecological disorders such as endometriosis, menorrhagia, meno-metrorrhagia, pre-menstrual syndrome and dysmenorrhoea are also contemplated.

## FIGURES

Figure 1

Chemical structures of etonogestrel heptanoate (etonogestrel enanthate), etonogestrel nonanoate, etonogestrel decanoate, etonogestrel undecanoate, etonogestrel dodecanoate, etonogestrel tridecanoate, and etonogestrel pentadecanoate.

Figure 2a

Effect of one intramuscular (IM) injection of etonogestrel, etonogestrel heptanoate (etonogestrel enanthate), etonogestrel nonanoate and etonogestrel undecanoate on plasma levels of etonogestrel in male intact rabbits. Means and SEM of N=3.

Figure 2b

Effect of one intramuscular (IM) injection of etonogestrel heptanoate (etonogestrel enanthate), etonogestrel nonanoate, etonogestrel decanoate, etonogestrel undecanoate, etonogestrel dodecanoate, etonogestrel tridecanoate on plasma levels of etonogestrel in male intact rabbits. Means and SEM of N=3.

## DETAILED DESCRIPTION OF THE INVENTION

The subject invention provides the compounds etonogestrel decanoate, etonogestrel undecanoate, and etonogestrel dodecanoate.

The subject invention contemplates a contraceptive and/or HRT kit comprising a contraceptively and/or therapeutically effective amount of etonogestrel decanoate and/or etonogestrel undecanoate and/or etonogestrel dodecanoate for both male and female contraception and HRT.

5

The subject invention further provides a use of a contraceptively and/or therapeutically effective amount of etonogestrel decanoate and/or etonogestrel undecanoate and/or etonogestrel dodecanoate for the preparation of a medicament for contraception and/or HRT. In a preferred embodiment, the medicament is for male contraception and/or male HRT. In another embodiment, the medicament is for female contraception and/or female HRT.

10

The subject invention further contemplates a method of contraception and/or HRT comprising administering to a subject a contraceptively and/or therapeutically effective amount of etonogestrel decanoate and/or etonogestrel undecanoate and/or etonogestrel dodecanoate. In a preferred embodiment, the subject is a male subject. In another embodiment, the subject is a female subject.

15

The subject invention additionally provides a use of a therapeutically effective amount of etonogestrel decanoate and/or etonogestrel undecanoate and/or etonogestrel dodecanoate for the preparation of a medicament for the treatment and/or prevention of female gynaecological disorders such as endometriosis, menorrhagia, metrorrhagia, pre-menstrual syndrome and dysmenorrhoea.

20

The subject invention further contemplates a method of treatment and/or prevention of female gynaecological disorders such as endometriosis, menorrhagia, metrorrhagia, pre-menstrual syndrome and dysmenorrhoea comprising administering to a female subject a therapeutically effective amount of etonogestrel decanoate and/or etonogestrel undecanoate and/or etonogestrel dodecanoate.

25

30

The compounds of the subject invention can be administered via any suitable route available to the skilled person.

In the case of oral administration, a solid dosage unit such as a tablet or a capsule is contemplated. The compounds of the invention can be formulated with a pharmaceutically acceptable carrier, such as described in the standard reference, Gennaro *et al*, *Remington: The Science and Practice of Pharmacy*, (20th ed., Lippincott Williams & Wilkins, 2000, see especially Part 5: Pharmaceutical Manufacturing). The compounds of the invention and the pharmaceutically acceptable carrier may be compressed into solid dosage units, such as pills, tablets, or be processed into capsules or suppositories. By means of pharmaceutically suitable liquids the compounds can also be applied as an injection preparation in the form of a solution, suspension, emulsion, or as a spray, *e.g.* nasal spray. For making dosage units, *e.g.* tablets, the use of conventional additives such as fillers, colorants, polymeric binders, lubricants, flow enhancers, glidants and the like is contemplated. In general any pharmaceutically acceptable additive which does not interfere with the function of the active compounds can be used. The compounds of the invention may also be included in an implant, a vaginal ring, a patch, a gel, and the like.

Suitable carriers with which the compositions can be administered include lactose, starch, cellulose derivatives and the like, or mixtures thereof used in suitable amounts.

The dose of and regimen of administration of the compounds of the invention, or a pharmaceutical composition thereof, to be administered will depend on the therapeutic effect to be achieved and will vary with the route of administration, and the age and condition of the individual subject to whom the medicament is to be administered, and/or the particular contraceptive or HRT regimen in which it is used.

Typical dosage amounts are 0.001-5 mg per kg body weight.

The present invention is further described in the following example which is not in any way intended to limit the scope of the invention as claimed.

**EXAMPLE - Kinetics of etonogestrel C7, C9, C10, C11, C12 and C13 esters in rabbits**

The following etonogestrel esters were prepared and tested in rabbits:

- Etonogestrel heptanoate
- Etonogestrel nonanoate
- Etonogestrel decanoate
- Etonogestrel undecanoate
- 5 • Etonogestrel dodecanoate
- Etonogestrel tridecanoate

Etonogestrel pentadecanoate was also prepared.

10 Figure 1 shows the chemical structure of these compounds.

As a reference, ctonogestrel was also included.

*Preparation of etonogestrel esters*

15 General methodology for the preparation of esters from alcohols can be found in e.g. Greene, T.W. et al, "Protective groups in organic synthesis", John Wiley & Sons, NY, 1999 (third edition). Preparation of esters from tertiary alcohols (like ctonogestrel) can be accomplished by several techniques, for instance:

- 1) tertiary alcohol, carboxylic acid, trifluoroacetic acid-anhydride, DE 1013284
- 20 (1956); 2) tertiary alcohol, acid chloride, pyridine, Watson, T.G. et al, Steroids 41, 255 (1983); 3) tertiary alcohol, acid chloride, TIOEt, Shafice, A. et al, Steroids 41, 349 (1983), 4) tertiary alcohol, carboxylic acid-anhydride, TsOH, benzene, Johnson, A.L., Steroids, 20, 263 (1972); and 5) tertiary alcohol, carboxylic acid-anhydride, DMAP, CH<sub>2</sub>Cl<sub>2</sub>, Shafice, A. et al, Steroids 41, 349 (1983).

25

*Preparation of (17 $\alpha$ )-13-Ethyl-11-methylene-17-[[[(1-oxononyl)oxy]-18,19-dinorpregn-4-en-20-yn-3-one (etonogestrel nonanoate)*

- a) A solution of nonanoic acid (1.95 g) in dry toluene (8 ml) was cooled to 0 °C and treated with trifluoroacetic acid anhydride (2.6 g). After 30 min. stirring, (17 $\alpha$ )-
- 30 13-ethyl-17-hydroxy-11-methylene-18,19-dinorpregn-4-en-20-yn-3-one (ctonogestrel, 2.0 g) in dry toluene (15 ml) was added and the reaction mixture was stirred for 17 h at room temperature. The reaction mixture was washed with water, a saturated aqueous solution of sodium hydrogen carbonate, water, and

brine. The organic phase was dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography (toluene/ethyl acetate 95:5). The product (2.08 g) was dissolved in ethyl acetate (40 ml), cooled to 0 °C, and stirred with aqueous sodium hydroxide (1 M, 13 ml) for 2 h. The mixture was extracted with ethyl acetate; the combined organic phases were washed with ice-cold aqueous sodium hydroxide (1 M), water and brine, dried and concentrated under reduced pressure. Column chromatography afforded (17 $\alpha$ )-13-ethyl-11-methylene-17-[[[(1-oxononyl)oxy]-18,19-dinorpregn-4-en-20-yn-3-one (1.25 g). <sup>1</sup>H-NMR (CDCl<sub>3</sub>):  $\delta$  5.89 (m, 1H), 5.08 (bs, 1H), 4.85 (bs, 1H), 2.82 (ddd, 1H, J = 14.8, 9.5 and 6.3 Hz), 2.73 (d, 1H, J = 12.8 Hz), 2.69-2.19 (m), 2.63 (s, 1H), 2.11 (m, 1H), 1.90-1.21 (m), 1.15 (m, 1H), 1.05 (t, 3H, J = 7.5 Hz), 0.88 (t, 3H, J = 7.1 Hz). Measured mass [M+H]<sup>+</sup> 465.3358. Calculated mass [M+H]<sup>+</sup> 465.3363.

In a manner analogous to the procedure described above, etonogestrel heptanoate, etonogestrel decanoate, etonogestrel undecanoate, etonogestrel dodecanoate, etonogestrel tridecanoate, and etonogestrel pentadecanoate were prepared:

- b) (17 $\alpha$ )-13-Ethyl-11-methylene-17-[[[(1-oxoheptyl)oxy]-18,19-dinorpregn-4-en-20-yn-3-one (etonogestrel heptanoate). <sup>1</sup>H-NMR (CDCl<sub>3</sub>):  $\delta$  5.89 (m, 1H), 5.08 (bs, 1H), 4.85 (bs, 1H), 2.82 (ddd, 1H, J = 14.8, 9.5 and 6.3 Hz), 2.73 (d, 1H, J = 12.6 Hz), 2.68-2.19 (m), 2.63 (s, 1H), 2.11 (m, 1H), 1.90-1.24 (m), 1.15 (m, 1H), 1.05 (t, 3H, J = 7.5 Hz), 0.89 (t, 3H, J = 7.1 Hz). Measured mass [M+H]<sup>+</sup> 437.3027. Calculated mass [M+H]<sup>+</sup> 437.3050.
- c) (17 $\alpha$ )-13-Ethyl-11-methylene-17-[[[(1-oxodecyl)oxy]-18,19-dinorpregn-4-en-20-yn-3-one (etonogestrel decanoate). <sup>1</sup>H-NMR (CDCl<sub>3</sub>):  $\delta$  5.89 (bs, 1H), 5.08 (bs, 1H), 4.84 (bs, 1H), 2.82 (m, 1H), 2.73 (d, 1H, J = 12.6 Hz), 2.67-2.18 (m), 2.63 (s, 1H), 2.11 (m, 1H), 1.90-1.21 (m), 1.15 (m, 1H), 1.06 (t, 3H, J = 7.5 Hz), 0.88 (t, 3H, J = 7.1 Hz). Measured mass [M+H]<sup>+</sup> 479.3508. Calculated mass [M+H]<sup>+</sup> 479.3519.
- d) (17 $\alpha$ )-13-Ethyl-11-methylene-17-[[[(1-oxoundecyl)oxy]-18,19-dinorpregn-4-en-20-yn-3-one (etonogestrel undecanoate). <sup>1</sup>H-NMR (CDCl<sub>3</sub>):  $\delta$  5.89 (m, 1H), 5.08 (bs, 1H), 4.85 (bs, 1H), 2.82 (ddd, 1H, J = 14.8, 9.5 and 6.3 Hz), 2.73 (d, 1H, J =

12.6 Hz), 2.68-2.18 (m), 2.63 (s, 1H), 2.11 (m, 1H), 1.90-1.21 (m), 1.06 (t, 3H, J = 7.5 Hz), 0.88 (t, 3H, J = 7.1 Hz). Measured mass  $[M+H]^+$  493.3664. Calculated mass  $[M+H]^+$  493.3676.

- 5 e) (17 $\alpha$ )-13-Ethyl-11-methylene-17-[[[(1-oxododecyl)oxy]-18,19-dinorpregn-4-en-20-yn-3-one (etonogestrel dodecanoate).  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ ):  $\delta$  5.89 (bs, 1H), 5.08 (bs, 1H), 4.85 (bs, 1H), 2.82 (m, 1H), 2.73 (d, 1H, J = 12.6 Hz), 2.65-2.18 (m), 2.64 (s, 1H), 2.11 (m, 1H), 1.90-1.20 (m), 1.15 (m, 1H), 1.06 (t, 3H, J = 7.5 Hz), 0.88 (t, 3H, J = 7.1 Hz). Measured mass  $[M+H]^+$  507.3829. Calculated mass  $[M+H]^+$  507.3832.
- 10 f) (17 $\alpha$ )-13-Ethyl-11-methylene-17-[[[(1-oxotridecyl)oxy]-18,19-dinorpregn-4-en-20-yn-3-one (etonogestrel tridecanoate).  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ ):  $\delta$  5.89 (bs, 1H), 5.08 (bs, 1H), 4.85 (bs, 1H), 2.82 (m, 1H), 2.73 (d, 1H, J = 12.6 Hz), 2.65-2.18 (m), 2.64 (s, 1H), 2.11 (m, 1H), 1.90-1.20 (m), 1.15 (m, 1H), 1.06 (t, 3H, J = 7.5 Hz), 0.89 (t, 3H, J = 7.1 Hz). Measured mass  $[M+H]^+$  521.4007. Calculated mass  $[M+H]^+$  521.3989.
- 15 g) (17 $\alpha$ )-13-Ethyl-11-methylene-17-[[[(1-oxopentadecyl)oxy]-18,19-dinorpregn-4-en-20-yn-3-one (etonogestrel pentadecanoate).  $^1\text{H-NMR}$  ( $\text{CDCl}_3$ ):  $\delta$  5.89 (bs, 1H), 5.08 (bs, 1H), 4.85 (bs, 1H), 2.82 (m, 1H), 2.73 (d, 1H, J = 12.6 Hz), 2.65-2.19 (m), 2.63 (s, 1H), 2.11 (m, 1H), 1.90-1.20 (m), 1.15 (m, 1H), 1.06 (t, 3H, J = 7.5 Hz), 0.89 (t, 3H, J = 7.1 Hz). Measured mass  $[M+H]^+$  549.4278. Calculated mass  $[M+H]^+$  549.4302.
- 20

#### *Pharmacokinetics studies in the rabbit*

- For the determination of the pharmacokinetic profile of the different etonogestrel-esters after parenteral application, i.m. application in the castrated rabbit model was chosen instead of s.c. Briefly, rabbits were injected once (day 1) with indicated etonogestrel-esters at 20 mg/kg in arachis oil (with a concentration of 40 mg/ml). At day 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 21, 28, 35, 49, 63, 77, 92, 106, 120 and 133 blood was collected from the ear arteria, in EDTA-containing tubes. EDTA plasma was prepared (1500g, 15 min) and stored at -20°C. With LC-MSMS the amount of parent compound (etonogestrel) was determined in these samples. The lower limit of this new assay is 0.5 nmol/l, from 0-250 nmol/l a linear curve was obtained with a correlation coefficient of 0.9998.
- 25
- 30

As shown in Figure 2a, etonogestrel itself resulted in very high peak levels (200 nmol/l), which declined in 28 days to levels of etonogestrel below 1 nmol/l.

5 Etonogestrel-heptanoate also gave rise to high initial peak levels of etonogestrel (120 nmol/l). Etonogestrel nonanoate gave lower peak levels and extended duration with serum levels of etonogestrel above 1 nmol/l. As compared to the other two esters in Figure 2a, etonogestrel undecanoate gave the most optimal balance between initial peak levels (maximum of 13 nmol/l after eight days) and duration of action (more than 92 days above 1 nmol/l).

10 As shown in Figure 2b, etonogestrel decanoate gave an initial peak level of 24 nmol/l after 5 days whereas etonogestrel dodecanoate gave an initial peak level of 9 nmol/l after 8 days. With etonogestrel tridecanoate, no initial levels of etonogestrel were observed.

From Figures 2a and 2b, it can be seen that preferred etonogestrel esters are  
15 etonogestrel decanoate, etonogestrel undecanoate, and etonogestrel dodecanoate.



## CLAIMS

1. Etonogestrel undecanoate.
- 5 2. Etonogestrel decanoate.
3. A contraceptive and/or HRT kit comprising a contraceptively and/or therapeutically effective amount of etonogestrel undecanoate and/or  
10 etonogestrel decanoate and/or etonogestrel dodecanoate.
4. A kit according to claim 3 for male contraception and/or male HRT.
5. A kit according to claim 3 for female contraception and/or female HRT.
- 15 6. A use of a contraceptively and/or therapeutically effective amount of etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate for the preparation of a medicament for contraception and/or HRT.
- 20 7. A use according to claim 6 wherein the medicament is for male contraception and/or male HRT.
8. A use according to claim 6 wherein the medicament is for female  
25 contraception and/or female HRT.
9. A method of contraception and/or HRT comprising administering to a subject a contraceptively and/or therapeutically effective amount of etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate.
- 30 10. A method according to claim 9 wherein the subject is a male subject.
11. A method according to claim 9 wherein the subject is a female subject.

12. A use of a therapeutically effective amount of etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate for the preparation of a medicament for the treatment and/or prevention of a female gynaecological disorder.
- 5
13. A use according to claim 12 wherein the female gynaecological disorder is selected from the group consisting of endometriosis, menorrhagia, metrorrhagia, pre-menstrual syndrome and dysmenorrhoea.
- 10
14. A method of treating and/or preventing a female gynaecological disorder comprising administering to a female subject a therapeutically effective amount of etonogestrel undecanoate and/or etonogestrel decanoate and/or etonogestrel dodecanoate effective to treat and/or prevent the disorder.
- 15
15. A method according to claim 14 wherein the female gynaecological disorder is selected from the group consisting of endometriosis, menorrhagia, metrorrhagia, pre-menstrual syndrome and dysmenorrhoea.
- 20
16. Etonogestrel dodecanoate.

Figure 1




Figure 2a





Figure 2b



C7: Etonogestrel heptanoate

5 C9: Etonogestrel nonanoate

C10: Etonogestrel decanoate

C11: Etonogestrel undecanoate

C12: Etonogestrel dodecanoate

C13: Etonogestrel tridecanoate

10

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/50187

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07J1/00 A61K31/565 A61P5/34 A61P15/16 A61P15/18

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07J A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included In the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 737 477 A (AKZO NOBEL NV) 16 October 1996 (1996-10-16) the whole document ----	1-10, 16
Y	DE 196 13 698 A (SCHERING AG) 23 January 1997 (1997-01-23) the whole document ----	1-10, 16
A	EP 0 129 947 A (WORLD HEALTH ORG) 2 January 1985 (1985-01-02) the whole document ----- -/--	1, 3

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

6 November 2003

Date of mailing of the international search report

17/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

de Nooy, A

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 03/50187

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>GUERIN J F ET AL: "INHIBITION OF SPERMATOGENESIS IN MEN USING VARIOUS COMBINATIONS OF ORAL PROGESTAGENS AND PERCUTANEOUS OR ORAL ANDROGENS" INTERNATIONAL JOURNAL OF ANDROLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 11, no. 3, 1988, pages 187-199, XP000917371 ISSN: 0105-6263 cited in the application the whole document</p> <p>-----</p>	3

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/50187

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 0737477	A	16-10-1996	AU 692504 B2	11-06-1998
			AU 1281895 A	17-07-1995
			BR 9408457 A	05-08-1997
			EP 0737477 A1	16-10-1996
			FI 962618 A	25-06-1996
			NO 962694 A	26-06-1996
			NZ 277552 A	26-01-1998
			CA 2176824 A1	06-07-1995
			CN 1135716 A	13-11-1996
			CZ 9601877 A3	15-01-1997
			HU 75159 A2	28-04-1997
			WO 9517896 A1	06-07-1995
			ZA 9410333 A	04-12-1995
DE 19613698	A	23-01-1997	DE 19613698 A1	23-01-1997
			AU 6614096 A	18-02-1997
			WO 9703709 A1	06-02-1997
			EP 0848620 A1	24-06-1998
			JP 11509222 T	17-08-1999
			ZA 9606083 A	19-06-1998
EP 0129947	A	02-01-1985	AT 37185 T	15-09-1988
			DE 3474024 D1	20-10-1988
			EP 0129947 A2	02-01-1985